Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Completed 10Recruiting 7Active not recruiting 7Unknown 5Withdrawn 3Terminated 3

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5CNS 5NET 2

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 221Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

anlotinib 2lutetium Lu 177 dotatate 1Temozolomide 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Paraganglioma × Clear all
NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
10 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05133349 2021-11-24

EASOAIPPGL

Nanjing First Hospital, Nanjing Medical University

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡